To include your compound in the COVID-19 Resource Center, submit it here.

Amgen takes a BiTE with Micromet deal

Amgen Inc. (NASDAQ:AMGN) partnered with Micromet Inc. (NASDAQ:MITI) to develop bispecific T cell

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE